Financial Performance Expectations - The company expects a net loss for the fiscal year 2024, estimated between 290 million and 390 million CNY, compared to a loss of 195.32 million CNY in the same period of 2023[3] - The expected loss after deducting non-recurring items is projected to be between 296.45 million and 396.45 million CNY, compared to a loss of 231.62 million CNY in the previous year[3] - The company anticipates a decrease in non-recurring gains contributing approximately 6.45 million CNY to net profit, a reduction of 29.85 million CNY compared to the same period last year[6] Performance Decline Factors - The decline in performance is attributed to changes in market supply and demand for pharmaceutical intermediates and composite additives, leading to reduced sales volume and price declines[5] - The company has recognized an impairment provision of 259.85 million CNY for assets showing signs of impairment[6] Financial Reporting and Caution - The financial data in the earnings forecast has not been audited by a registered accountant, but there are no significant discrepancies with the auditing firm[4] - The company emphasizes the importance of cautious decision-making for investors due to the preliminary nature of the earnings forecast[7] - The detailed financial data will be disclosed in the annual report for 2024[7]
尔康制药(300267) - 2024 Q4 - 年度业绩预告